Clinical Trial Update: Homoharringtonine in Treating Patients With Refractory Acute Promyelocytic Leukemia [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial of Homoharringtonine for patients with refractory acute promyelocytic leukemia has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Promyelocytic Leukemia
• Leukemia

Drugs mentioned

• Homoharringtonine (homoharringtonine)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Leukemia | Phase 1, Phase 2 | Status: WITHDRAWN